VERAXA Biotech AG (NASDAQ: VRXA) announced it has received Scientific Advice from Germany’s Paul-Ehrlich-Institute regarding the underlying biology and proposed non-clinical development plan for its lead proprietary BiTAC-TCE cancer therapy program. The regulatory feedback provides greater clarity on the company’s proposed development strategy and indicates that the agency understands the biological rationale behind its dual-targeting, conditionally active BiTAC-TCE platform, representing an early step in advancing the program toward clinical development.
This news matters because it marks a significant milestone for VERAXA as it moves its lead candidate from preclinical research toward human trials. The BiTAC-TCE platform is designed to selectively target cancer cells expressing both intended targets while sparing cells expressing only one target, potentially reducing off-tumor toxicity common with traditional T-cell engagers. According to the company, preclinical data presented at the American Association for Cancer Research Annual Meeting 2026 demonstrated a favorable safety profile with efficacy comparable to a traditional T-cell engager, supporting the potential for an improved therapeutic index.
For the biotech industry, this development underscores the increasing focus on conditionally active bispecific antibodies that aim to widen the therapeutic window. If successful, VERAXA’s approach could lead to safer and more effective cancer immunotherapies, benefiting patients who currently face severe side effects from conventional T-cell engaging therapies. The regulatory feedback from the Paul-Ehrlich-Institute, Germany’s federal authority for vaccines and biomedicines, adds credibility to the platform’s scientific foundation.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. The company is building a pipeline of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats, guided by rigorous quality-by-design principles.
Investors and industry watchers will be monitoring VERAXA’s progress as it prepares for clinical development. The company’s newsroom provides updates at http://ibn.fm/VRXA. The full press release can be viewed at https://ibn.fm/jpXam.
The impact of this announcement extends to patients and healthcare providers, as a successful BiTAC-TCE therapy could offer a new treatment option with fewer side effects. For VERAXA, clear regulatory guidance de-risks the development pathway and could accelerate timelines. As the company moves toward the clinic, the preclinical data supporting an improved therapeutic index will be crucial for attracting further investment and partnership opportunities.
